Larimar Therapeutics names John B. Harlow Jr. President and COO; $560K salary, 850K-share equity grant

Larimar Therapeutics, Inc.

Harlow, 51, was most recently Chief Commercial Officer at Esperion Therapeutics (Nov 2025-Sep 2026); earlier CCO roles at Melinta Therapeutics, Baudax Bio and Recro Pharma.
Employment effective September 29, 2026: base salary $560,000 per year, $35,000 cash signing bonus, target annual bonus of 40% of salary (2026 prorated).
Inducement awards under Nasdaq Rule 5635(c)(4): 800,000 stock options struck at the Sept 29, 2026 closing price and 50,000 restricted stock units.
Options vest 25% on the first anniversary and the remaining 75% in 36 monthly installments; RSUs vest in four equal annual installments beginning on the first anniversary.
Severance if terminated without cause: 9 months of salary plus 9 months COBRA; 12 months of salary plus target bonus and COBRA if terminated within one year after a change in control.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.